Back to User profile » Professor Bing Sun
Papers published by Professor Bing Sun:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
Li XY, Rao Y, Sun B, Mao XM
International Journal of General Medicine 2022, 15:3977-3989
Published Date: 12 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Brain metastases from breast cancer may respond to endocrine therapy: report of two cases
Wang Q, Sun B, Liu C, Shi S, Ding L, Liu J, Wu S
OncoTargets and Therapy 2019, 12:1389-1393
Published Date: 19 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease
Liu C, Sun B, Xu B, Meng X, Li L, Cong Y, Liu J, Wang Q, Xuan L, Song Q, Wu S
Cancer Management and Research 2018, 10:1749-1761
Published Date: 26 June 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients
Liu C, Wang W, Meng XY, Sun B, Cong Y, Liu JN, Wang Q, Liu GX, Wu SK
OncoTargets and Therapy 2018, 11:2131-2139
Published Date: 12 April 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer
Liu C, Huang Z, Wang QS, Sun B, Ding LJ, Meng XY, Wu SK
OncoTargets and Therapy 2016, 9:4653-4660
Published Date: 27 July 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
Sun B, Ding LJ, Wu S, Meng XY, Song S
OncoTargets and Therapy 2016, 9:3997-4003
Published Date: 1 July 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Bilateral breast adenocarcinomas with EML4—ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?
Liu C, Ding L, Sun B, Wu S,
OncoTargets and Therapy 2016, 9:3589-3593
Published Date: 16 June 2016